Albert Qin

697 total citations
48 papers, 319 citations indexed

About

Albert Qin is a scholar working on Genetics, Rheumatology and Oncology. According to data from OpenAlex, Albert Qin has authored 48 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 21 papers in Rheumatology and 17 papers in Oncology. Recurrent topics in Albert Qin's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers), Eosinophilic Disorders and Syndromes (16 papers) and Hepatitis C virus research (8 papers). Albert Qin is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers), Eosinophilic Disorders and Syndromes (16 papers) and Hepatitis C virus research (8 papers). Albert Qin collaborates with scholars based in United States, Taiwan and Japan. Albert Qin's co-authors include Yi‐Wen Huang, Pei‐Jer Chen, Oleh Zagrijtschuk, Raymond Urbanski, James J. O’Leary, Rong‐Nan Chien, Norio Komatsu, S. Zildjian, John Mascarenhas and Toshiaki Sato and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Albert Qin

42 papers receiving 295 citations

Peers

Albert Qin
Kathrin Schönberg Germany
Émilie Ducourau France
Elisabetta Calistri Italy
Miguel Piris‐Villaespesa Spain
Nimitha R. Mathew Sweden
Houria Hendel‐Chavez France
A.C. Virgili Manrique Spain
Aimaz Afrough United States
Priscilla F. Kerkman Netherlands
Takeru Nambu Japan
Kathrin Schönberg Germany
Albert Qin
Citations per year, relative to Albert Qin Albert Qin (= 1×) peers Kathrin Schönberg

Countries citing papers authored by Albert Qin

Since Specialization
Citations

This map shows the geographic impact of Albert Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Qin more than expected).

Fields of papers citing papers by Albert Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Qin. The network helps show where Albert Qin may publish in the future.

Co-authorship network of co-authors of Albert Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Qin. A scholar is included among the top collaborators of Albert Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Qin. Albert Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Duan, Minghui, Prithviraj Bose, Anthony M. Hunter, et al.. (2025). Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera. Current Hematologic Malignancy Reports. 20(1). 13–13.
2.
Abu‐Zeinah, Ghaith, Anthony M. Hunter, Joseph J. Shatzel, et al.. (2025). Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients. PubMed. 2(4). 100167–100167.
3.
Qin, Albert, Kazuya Shimoda, Rongfeng Fu, et al.. (2025). Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera. Pharmacology Research & Perspectives. 13(3). e70109–e70109. 1 indexed citations
4.
Medlicott, Natalie J., Yi Wang, Noelyn Hung, et al.. (2024). A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study. Pharmaceutics. 16(5). 602–602. 1 indexed citations
5.
Qin, Albert, Yaning Li, Jingjing Zhang, et al.. (2024). Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera. British Journal of Clinical Pharmacology. 90(6). 1493–1502. 6 indexed citations
6.
Lin, Lih‐Ling, et al.. (2024). A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer. Cancers. 16(17). 3052–3052. 1 indexed citations
7.
Kirito, Keita, Yuka Sugimoto, Akihiko Gotoh, et al.. (2024). Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. International Journal of Hematology. 120(6). 675–683. 4 indexed citations
8.
Abu‐Zeinah, Ghaith, Albert Qin, Harinder Gill, et al.. (2024). A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis. Annals of Hematology. 103(9). 3573–3583. 3 indexed citations
9.
Hung, Noelyn, Karen Eden, Wing‐Kai Chan, et al.. (2024). Oral docetaxel plus encequidar – a phase 1 clinical trial. Cancer Chemotherapy and Pharmacology. 94(3). 475–481. 1 indexed citations
10.
11.
Jin, Jie, Albert Qin, Weihong Shen, et al.. (2023). A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera. Future Oncology. 19(11). 753–761. 7 indexed citations
12.
Lo, Gin‐Ho, Wan‐Long Chuang, Hsing‐Tao Kuo, et al.. (2023). A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment. Journal of the Formosan Medical Association. 123(1). 55–61. 1 indexed citations
13.
14.
Qin, Albert. (2023). An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Frontiers in Oncology. 13. 1173467–1173467. 11 indexed citations
15.
Hong, Jin‐Bon, Po‐Yuan Wu, Albert Qin, et al.. (2022). Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics. 14(10). 2159–2159. 4 indexed citations
16.
Huang, Yi‐Wen, et al.. (2021). Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. Advances in Therapy. 38(9). 4756–4770. 14 indexed citations
17.
Huang, Yi‐Wen, Chao‐Wei Hsu, Sheng‐Nan Lu, et al.. (2020). Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatology International. 14(6). 997–1008. 23 indexed citations
18.
Yu, Ming‐Lung, Chien‐Wei Su, Cheng‐Yuan Peng, et al.. (2020). Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. Journal of the Formosan Medical Association. 120(3). 956–964. 16 indexed citations
19.
Fossella, Frank V., Penella J. Woll, Paul Lorigan, et al.. (2009). Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC). Journal of Thoracic Oncology. 4. 8 indexed citations
20.
Sankhala, Kamalesh K., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors. Molecular Cancer Therapeutics. 6. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathrin Schönberg Breakdown of academic impact, for papers by Émilie Ducourau Breakdown of academic impact, for papers by Elisabetta Calistri Breakdown of academic impact, for papers by Miguel Piris‐Villaespesa Breakdown of academic impact, for papers by Nimitha R. Mathew Breakdown of academic impact, for papers by Houria Hendel‐Chavez Breakdown of academic impact, for papers by A.C. Virgili Manrique Breakdown of academic impact, for papers by Aimaz Afrough Breakdown of academic impact, for papers by Priscilla F. Kerkman Breakdown of academic impact, for papers by Takeru Nambu
Rankless by CCL
2026